Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 7, 2024
Daily News
August 7, 2024
- Japan’s Antibiotic Use Up 22.3% in 2023 after COVID Restrictions Lifted
August 7, 2024
- How Will Simplified Delisting, Elective Care Affect G1 Withdrawal Scheme?
August 7, 2024
- Anapeine Restriction Forcing Sandoz to Curb Supply of More Local Anesthetics
August 7, 2024
- Sandoz to Discontinue Paxil AGs as Originator Pulls Out
August 7, 2024
- Kyorin, Jikei Startup Ink Option Deal for Respiratory Disease Treatment
August 7, 2024
- NCC Offshoot’s 1st CAR-T Therapy Set to Enter Clinic Next Year: CEO
August 7, 2024
- Santen Axes Diquas LX Outlook to Zero for Now as Supply Halt Continues
August 7, 2024
- Santen Snags Asian Rights to Cloudbreak’s Topical Pterygium Drug
August 7, 2024
- Keytruda Tops Japan Sales Ranking for 10th Straight Month: Encise
August 7, 2024
- Japan CDMO Market Up Only Slightly in 2023 as COVID Windfall Falters: Report
August 7, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…